American Journal of Cardiology
Volume 103, Issue 6 , Pages 839-844, 15 March 2009

A Propensity-Matched Study of Elevated Jugular Venous Pressure and Outcomes in Chronic Heart Failure

  • Philippe Meyer, MD

      Affiliations

    • Montreal Heart Institute, Montreal, Canada
  • ,
  • O. James Ekundayo, MD, DrPH

      Affiliations

    • University of Alabama at Birmingham, Birmingham, Alabama
  • ,
  • Chris Adamopoulos, MD, PhD

      Affiliations

    • Papageorgiou General Hospital, Thessaloniki, Greece
  • ,
  • Marjan Mujib, MBBS

      Affiliations

    • University of Alabama at Birmingham, Birmingham, Alabama
  • ,
  • Inmaculada Aban, PhD

      Affiliations

    • University of Alabama at Birmingham, Birmingham, Alabama
  • ,
  • Michel White, MD

      Affiliations

    • Montreal Heart Institute, Montreal, Canada
  • ,
  • Wilbert S. Aronow, MD

      Affiliations

    • New York Medical College, Valhalla, New York
  • ,
  • Ali Ahmed, MD, MPH

      Affiliations

    • University of Alabama at Birmingham, Birmingham, Alabama
    • VA Medical Center, Birmingham, Alabama
    • Corresponding Author InformationCorresponding author: Tel: 205-934-9632; fax: 205-975-7099

Received 27 August 2008; received in revised form 18 November 2008; accepted 18 November 2008.

The independence of association between elevated jugular venous pressure (JVP) and outcomes in heart failure (HF) has not been well studied. The objective of propensity-matched study was to determine if an elevated JVP had intrinsic associations with outcomes in chronic systolic and diastolic HF. Of the 7,788 participants in the Digitalis Investigation Group trial, 1,020 (13%) had elevated JVP at baseline. Propensity scores for elevated JVP were estimated for all patients based on 32 baseline characteristics and were used to match 827 pairs of patients with normal and elevated JVP. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated to compare outcomes associated with elevated versus normal JVP during 34 months of median follow-up. Before matching, all-cause mortality occurred in 31% and 47% (unadjusted HR 1.70, 95% CI 1.54 to 1.88, p <0.0001), and all-cause hospitalization occurred in 60% and 71% (unadjusted HR 1.35, 95% CI 1.25 to 1.47, p <0.0001) of patients with normal and elevated JVP, respectively. After matching, all-cause mortality occurred in 48% and 45% (matched HR 0.95, 95% CI 0.80 to 1.12, p = 0.521), and all-cause hospitalization occurred in 70% and 70% (matched HR 0.97, 95% CI 0.87 to 1.09, p = 0.613) of patients with normal and elevated JVP, respectively. Elevated JVP had no intrinsic associations with cardiovascular mortality (matched HR 0.93, 95% CI 0.77 to 1.12, p = 0.440) or hospitalization for HF (matched HR 0.94, 95% CI 0.78 to 1.14, p = 0.532). In conclusion, an elevated JVP is a marker of higher burden of sickness and poor outcomes. However, elevated JVP had no intrinsic association with mortality or hospitalization in chronic HF.

 

 Dr. Ahmed is supported by a grant (R01-HL085561) from the National Heart, Lung, and Blood Institute (NHLBI), Bethesda, Maryland, and a generous gift from Ms. Jean B. Morris of Birmingham, Alabama.The Digitalis Investigation Group (DIG) study was conducted and supported by the NHLBI in collaboration with the DIG Investigators. This manuscript was prepared using a limited access dataset obtained by the NHLBI and does not necessarily reflect the opinions or views of the DIG Study or the NHLBI.

PII: S0002-9149(08)02122-X

doi:10.1016/j.amjcard.2008.11.045

American Journal of Cardiology
Volume 103, Issue 6 , Pages 839-844, 15 March 2009